Compare BFS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | EVO |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | United States | Germany |
| Employees | 98 | 4553 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 934.1M |
| IPO Year | N/A | N/A |
| Metric | BFS | EVO |
|---|---|---|
| Price | $33.67 | $2.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $44.00 | $7.00 |
| AVG Volume (30 Days) | 40.5K | ★ 95.9K |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.30 | $1.37 |
| Revenue Next Year | $5.67 | $10.05 |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.16 | $2.31 |
| 52 Week High | $35.45 | $4.80 |
| Indicator | BFS | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 41.07 |
| Support Level | $33.14 | $2.32 |
| Resistance Level | $34.99 | $3.78 |
| Average True Range (ATR) | 0.81 | 0.09 |
| MACD | -0.15 | -0.06 |
| Stochastic Oscillator | 30.82 | 19.16 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.